M-ROSE Combined With mNGS in Severe Hospital-acquired Pneumonia
A Multi-center Prospective Clinical Study of M-ROSE Combined With mNGS to Guide the Individualized Anti-infection Treatment, Prevention and Control of Drug-resistant Bacteria in Severe Hospital-acquired Pneumonia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yi Tao, Ph.D
- Phone Number: +8617797708263
- Email: taoyimmu@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100083
- Recruiting
- Yi Tao
-
Contact:
- Yi Tao
- Phone Number: 17797708263
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of severe hospital-acquired pneumonia
- Must have undergone bronchoalveolar lavage
Exclusion Criteria:
- BALF samples were not sent for mNGS examination
- Age < 18 years old
- The hospitalization days ≤ 3
- The clinical data are incomplete
- Mechanical ventilation time > 60 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: M-ROSE combined with mNGS group
The bronchoalveolar lavage fluid (BALF) of patients undergoes M-ROSE analysis and decide whether the samples are qualified, whether they indicate bacterial infection and identify pathogens, and the qualified samples are sent for mNGS analysis.
The individualized anti-infection treatment is comprehensively guided according to the results of M-ROSE, mNGS and clinical examinations.
|
The M-ROSE analysis process consists of 3 procudures.
|
|
No Intervention: mNGS group
BALF samples were directly sent for mNGS analysis, and anti-infective treatment was guided according to clinical examinations.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mortality
Time Frame: During the intervention.
|
Alive or Dead.
|
During the intervention.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood leukocyte ratio tread
Time Frame: During the intervention.
|
The changing of blood leukocyte ratio
|
During the intervention.
|
|
28 day outcome
Time Frame: 28 days after admission
|
Live or dead.
|
28 days after admission
|
|
Blood neutriphil ratio tread
Time Frame: During the intervention.
|
The changing of blood neutriphil ratio tread
|
During the intervention.
|
|
Blood interleukin 6 tread
Time Frame: During the intervention.
|
The changing of blood interleukin 6 tread
|
During the intervention.
|
|
Blood C-reactive protein
Time Frame: During the intervention.
|
The changing of blood C-reactive protein
|
During the intervention.
|
|
Blood procalcitonin tread
Time Frame: During the intervention.
|
The changing of blood procalcitonin tread
|
During the intervention.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lixin Xie, Ph.D, Chinese PLA General Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- shoufa2022-1-5091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.